Detail akcie PACIFIC online

Business Summary: Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Pacific Biosciences of California Inc revenues decreased 4% to $37.2M. Net loss increased from $78.2M to $426.1M. Revenues reflect Instrument revenue segment decrease of 42% to $11M, North America segment decrease of 8% to $16.3M, Asia Pacific segment decrease of 9% to $11.6M. Higher net loss reflects Total Amort of Intangibles-excl Goodwill increase from $5.5M to $362M (expense), Other income.